Actively Recruiting
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2023-07-19
24
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Henoch Schönlein purpura (HSP) is the most common type of vasculitis in children, with an incidence of \~10/100,000, whereas \>90% of the patients develop symptoms at \<10 years of age. Although HSP is generally a self-limiting disease, it may also lead to severe complications, such as intestinal intussusception, infarction and perforation, as well as end-stage renal disease. The management of HSP includes symptomatic treatment and immunosuppressive therapy in certain patients. Previous retrospective studies have reported that most patients with gastrointestinal (GI) symptoms may benefit from early usage of glucocorticoid, whereas there are still a part of HSP patients with GI did not achieved remission after administering of steroid. Therefore, the aim of the present study was to investigate the clinical features of refractory GI HSP and the clinical outcome of mycophenolate mofetil in these patients.
CONDITIONS
Official Title
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages range from 3 to 18 years old
- Diagnosis of Henoch-Sch�f6nlein purpura involving the digestive tract with symptoms like acute diffuse abdominal colic, intussusception, or gastrointestinal bleeding
- Refractory gastrointestinal HSP defined as no improvement after intravenous corticosteroid 2 mg/kg/day for 3 days or relapse during steroid tapering
- Parents or guardians provide informed consent
You will not qualify if you...
- Allergy to mycophenolate mofetil (MMF)
- Severe diseases including systemic malignancies, heart failure, liver or renal failure, immune deficiency, severe infections, organ transplant surgery, or urgent surgery needs
- Presence of other digestive system diseases
- Previous participation in MMF clinical trials
- Any other condition deemed inappropriate by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510120
Actively Recruiting
Research Team
H
Haiyan Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here